Autolus Therapeutics

AUTL

時価総額 $4.26億

Autolus Therapeutics (AUTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

LONDON and GAITHERSBURG, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced the online publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2026 meeting being held November 6-11, 2026 in Orlando, Florida.

LONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to obecabtagene autoleucel (obe-cel) for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN).

Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript

Autolus Therapeutics NASDAQ: AUTL reported second-quarter 2026 net product revenue of $45.7 million from sales of AUCATZYL, up from $26.2 million in the first quarter and $20.9 million a year earlier, as the company expanded treatment-center access and continued its commercial launch in the United States and United Kingdom.

LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its second quarter 2026 financial results and operational highlights before open of U.S. markets on Tuesday, August 11, 2026.

Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date FY 2026 sales guidance increased to $140 – $150 million, from $120 – $135 million Capital base strengthened through five-year, interest-only credit facility with $75 million funded at close Autolus to report Q2 2026 financial results on August 11, 2026 LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced preliminary second quarter 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date.

Autolus Therapeutics maintains a Buy rating, driven by ongoing execution in CAR T-cell therapy, especially with obe-cel in oncology and autoimmune diseases. Obe-cel's expansion into lupus nephritis and multiple sclerosis represents significant long-term upside, with pivotal data expected in 2027–2028 and a potentially underserved market niche. Despite modest revenue growth and a positive gross margin, AUTL faces a short cash runway, relying on restructuring and sales growth to extend liquidity into Q4 2027.

Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.

LONDON & GAITHERSBURG, Md., July 01, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 25,420 American Depositary Shares and 87,530 restricted stock units (RSUs), each representing an equal number of ordinary shares, to 13 employees pursuant to the Company's 2025 Inducement Plan.